Azitra, Inc. Research and Development Expense
Azitra, Inc. (AZTR) reported Research and Development Expense of $1.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Azitra, Inc. research and development expense for the quarter ending 2026-06-30 was $1.35M, a 3.59% decline year-over-year.
- Azitra, Inc. research and development expense for the quarter ending 2026-03-31 was $1.56M, a 24.84% increase year-over-year.
- Azitra, Inc. research and development expense for the quarter ending 2025-12-31 was $1.00M, a 10.04% decline year-over-year.
- Azitra, Inc. research and development expense for the quarter ending 2025-09-30 was $1.18M, a 16.17% increase year-over-year.
- Azitra, Inc. research and development expense for fiscal 2025 was $4.84M, a 2.38% increase from fiscal 2024.
- Azitra, Inc. research and development expense for fiscal 2024 was $4.72M, a 29.65% increase from fiscal 2023.
- Azitra, Inc. research and development expense for fiscal 2023 was $3.64M, a 40.25% decline from fiscal 2022.
- Azitra, Inc. research and development expense for fiscal 2022 was $6.10M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.35M 10-Q · filed 2026-08-12 | $2.91M 10-Q · filed 2026-08-12 | $3.92M derived: sum of 3 quarters · filed 2026-08-12 | $5.10M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $1.56M 10-Q · filed 2026-05-13 | $2.56M derived: sum of 2 quarters · filed 2026-05-13 | $3.74M derived: sum of 3 quarters · filed 2026-05-13 | $5.15M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $2.18M derived: sum of 2 quarters · filed 2026-02-27 | $3.59M derived: sum of 3 quarters · filed 2026-08-12 | $4.84M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $1.18M 10-Q · filed 2025-11-12 | $2.58M derived: sum of 2 quarters · filed 2026-08-12 | $3.83M 10-Q · filed 2025-11-12 | $4.95M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $1.40M 10-Q · filed 2026-08-12 | $2.65M 10-Q · filed 2026-08-12 | $3.77M derived: sum of 3 quarters · filed 2026-08-12 | $4.78M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $1.25M 10-Q · filed 2026-05-13 | $2.37M derived: sum of 2 quarters · filed 2026-05-13 | $3.38M derived: sum of 3 quarters · filed 2026-05-13 | $4.50M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $2.13M derived: sum of 2 quarters · filed 2026-02-27 | $3.25M derived: sum of 3 quarters · filed 2026-02-27 | $4.72M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $1.02M 10-Q · filed 2025-11-12 | $2.13M derived: sum of 2 quarters · filed 2025-11-12 | $3.61M 10-Q · filed 2025-11-12 | $5.12M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $1.12M 10-Q · filed 2025-08-11 | $2.59M 10-Q · filed 2025-08-11 | $4.10M derived: sum of 3 quarters · filed 2025-08-11 | $4.65M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $1.47M 10-Q · filed 2025-05-13 | $2.98M derived: sum of 2 quarters · filed 2025-05-13 | $3.53M derived: sum of 3 quarters · filed 2025-05-13 | $4.29M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $2.06M derived: sum of 2 quarters · filed 2025-02-24 | $2.81M derived: sum of 3 quarters · filed 2025-02-24 | $3.64M 10-K · filed 2025-02-24 | $3.81M 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $548.52K 10-Q · filed 2024-11-12 | $1.30M derived: sum of 2 quarters · filed 2024-11-12 | $2.13M 10-Q · filed 2024-11-12 | $2.19M 10-Q · filed 2023-11-14 | $3.81M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $754.95K 10-Q · filed 2024-08-12 | $812.84K 10-Q · filed 2023-08-14 | $1.58M 10-Q · filed 2024-08-12 | $1.64M 10-Q · filed 2023-08-14 | $3.26M derived: sum of 3 quarters · filed 2024-08-12 | $4.62M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $829.03K 10-Q · filed 2024-05-09 | $2.50M derived: sum of 2 quarters · filed 2024-05-09 | $3.87M derived: sum of 3 quarters · filed 2024-05-09 | $5.37M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $3.04M derived: sum of 2 quarters · filed 2024-03-15 | $4.54M derived: sum of 3 quarters · filed 2024-03-15 | $6.10M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $1.36M 10-Q · filed 2023-11-14 | $2.87M derived: sum of 2 quarters · filed 2023-11-14 | $4.43M 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | $1.51M 10-Q · filed 2023-08-14 | $3.06M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |